Last checked at 
(Sharecast News) - AstraZeneca said a study of its monoclonal antibody treatment, AZD7442, did not meet the main goal of preventing symptomatic Covid-19 in people exposed to the coronavirus in the past eight days.
Trial participants were unvaccinated adults older than 18 years with confirmed exposure to a person with the coronavirus, AstraZeneca said in a statement.
AZD7442 reduced the risk of developing symptomatic COVID-19 by 33% compared to a placebo, which was not statistically significant, it added.
The trial included 1,121 participants in a 2:1 randomisation AZD7442-to-placebo, with 23 cases of symptomatic Covid-19 accrued in the AZD7442 arm (23/749) and 17 cases accrued in the placebo arm (17/372). All participants had a negative SARS-CoV-2 antibody test on the day of dosing to exclude prior infection, and a nasopharyngeal swab was also collected and subsequently analysed for SARS-CoV-2 using an RT-PCR test to detect the virus.
"While this trial did not meet the primary endpoint against symptomatic illness, we are encouraged by the protection seen in the PCR negative participants following treatment with AZD7442," said AstraZeneca executive vice president Mene Pangalos
AstraZeneca is also studying the treatment in a pre-exposed patients trial and for preventing more severe disease.
AZD7442 is being developed with support from the US government. The company in March announced a deal with Washington to supply up to 500,000 doses of AZD7442 for $205m. The company said on Tuesday talks with officials regarding next steps on the deal are ongoing.
Today 10:04
AstraZeneca notes positive trial results for Calquence treatment
(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.
Read more